You are currently viewing a new version of our website. To view the old version click .
Medical Sciences Forum
  • Abstract
  • Open Access

1 November 2022

Annonaceous Acetogenins Reported for the First Time in the Leaves and Fruit’s Pulp of Annona atemoya †

,
and
The School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
*
Author to whom correspondence should be addressed.
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
This article belongs to the Proceedings The 8th International Electronic Conference on Medicinal Chemistry

Abstract

Annona atemoya is a commercially important fruiting plant belonging to the Annonaceae family. It is widely cultivated in tropical and subtropical continents. It is also known as the custard apple which is a hybrid between two Annonaceae species, those being Annona cherimola and Annona squamosa. This study aimed to investigate the phytochemical constituents and pharmacological activity of various parts of A. atemoya including leaves and fruit’s pulp. The leaves and fruits of A. atemoya were collected in July 2020 from a local farm in Queensland, air dried at room temperature (3 days–1 week) and then ground to a powder. The leaves and pulp were separately extracted with hexane, ethyl acetate and finally ethanol for three days each. The preliminary results of Thin layer chromatography (TLC) and Nuclear magnetic resonance (NMR) experiments indicated the presence of annonaceous acetogenins for the first time in the leaves and pulp as pink bands after reacting with Kedde reagent. For the leaves, ten compounds were identified, two of them were isolated and the other confirmed via NMR and MS analysis. The ethyl acetate extract of leaf was the richest in an abundance of acetogenins in comparison to the hexane extract. With regards to the fruit’s pulp, the concentration of acetogenins was very low compared to the leaves. Future studies will focus on testing either isolated compounds or crude extracts using various cancer cell lines.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13444/s1.

Author Contributions

Conceptualization, J.R.H.; methodology, B.S.M.A.K.; validation, J.R.H. and J.E.H. formal analysis, B.S.M.A.K.; investigation, B.S.M.A.K.; writing—original draft preparation, B.S.M.A.K.; writing—review and editing, J.R.H. and J.E.H.; supervision, J.R.H. and J.E.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.